采用拮抗剂早期停用和促性腺激素递减方案的改良柔性GnRH拮抗剂方案提高新鲜周期活产率:一项随机对照试验
该开放标签随机对照试验于2021年11月至2022年8月纳入546例卵巢反应正常的患者,1:1分配至改良拮抗剂方案组或常规拮抗剂方案组。改良方案采用促性腺激素递减并在hCG日停用GnRH拮抗剂,结果显示改良组每新鲜单胚胎移植周期活产率显著高于常规组(38.1% vs 27.5%,RR 1.39,95%CI 1.09-1.77,P=0.008)。
要点
- 改良GnRH拮抗剂方案(Gn递减+hCG日停用拮抗剂)可提高新鲜eSET周期活产率。
- 改良组活产率38.1%(104/273)vs 常规组27.5%(75/273),RR 1.39(95%CI 1.09-1.77),P=0.008。
- 两组获卵数、成熟卵数、2PN率、优质胚胎率、早期流产率及OHSS发生率无显著差异(P>0.05)。
核心结论
- 在卵巢反应正常的患者中,采用Gn递减方案并在hCG日停用GnRH拮抗剂的改良拮抗剂方案,可提高每新鲜eSET周期的活产率。
研究设计与样本
- 开放标签随机对照试验,于2021年11月至2022年8月开展,546例患者按1:1分配至改良GnRH拮抗剂方案组或常规拮抗剂方案组。
- 纳入IVF和ICSI周期,精子来源为伴侣新鲜或冷冻精液,或冷冻供精者射精标本。
- 主要结局为每新鲜单胚胎移植周期活产率;次要结局包括着床率、临床妊娠率、持续妊娠率、流产率、OHSS发生率及卵巢刺激临床结局。
- 试验在中国临床试验注册中心注册,注册号ChiCTR2100053453,注册日期2021年11月21日,首例患者入组日期2021年11月23日。
主要发现
- 意向性分析(ITT)人群中,改良组活产率显著高于常规组:38.1%(104/273)vs 27.5%(75/273),相对危险度1.39(95%CI 1.09-1.77),P=0.008。
- 符合方案分析(PP,纳入所有接受胚胎移植的患者)中,改良组活产率亦显著高于常规组:48.6%(103/212)vs 36.8%(74/201),相对危险度1.32(95%CI 1.05-1.66),P=0.016。
- ITT和PP分析中,改良组着床率、临床妊娠率和持续妊娠率均显著高于常规组(P<0.05)。
- 两组获卵数、成熟卵数、双原核(2PN)率、获胚数、囊胚形成率、优质胚胎率、早期流产率及OHSS发生率均无显著差异(P>0.05)。
- 两组基线人口学特征无显著差异。
临床怎么用
- 作者认为,对于卵巢反应正常的患者,采用Gn递减方案并在hCG日停用GnRH拮抗剂的改良拮抗剂方案可提高每新鲜eSET周期活产率。
局限性
- 该随机对照试验中受试者未对治疗分配设盲。
- 分析仅纳入年龄小于40岁且预后良好的女性,因此改良拮抗剂方案在卵巢储备低下的高龄患者中的应用尚需研究。
- 第5天择期单胚胎移植的样本量小,需要更大规模的试验来加强这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can pregnancy outcomes following fresh elective single embryo transfer (eSET) in gonadotropin-releasing hormone (GnRH) antagonist protocols increase using a gonadotropin (Gn) step-down approach with cessation of GnRH antagonist on the day of hCG administration (hCG day) in patients with normal ovarian response? SUMMARY ANSWER: The modified GnRH antagonist protocol using the Gn step-down approach and cessation of GnRH antagonist on the hCG day is effective in improving live birth rates (LBRs) per fresh eSET cycle. WHAT IS KNOWN ALREADY: Currently, there is no consensus on optimal GnRH antagonist regimens. Studies have shown that fresh GnRH antagonist cycles result in poorer pregnancy outcomes than the long GnRH agonist (GnRHa) protocol. Endometrial receptivity is a key factor that contributes to this phenomenon. STUDY DESIGN, SIZE, DURATION: An open label randomized controlled trial (RCT) was performed between November 2021 and August 2022. There were 546 patients allocated to either the modified GnRH antagonist or the conventional antagonist protocol at a 1:1 ratio. PARTICIPANTS/MATERIALS, SETTING, METHODS: Both IVF and ICSI cycles were included, and the sperm samples used were either fresh or frozen from the partner, or from frozen donor ejaculates. The primary outcome was the LBRs per fresh SET cycle. Secondary outcomes included rates of implantation, clinical and ongoing pregnancy, miscarriage, and ovarian hyperstimulation syndrome (OHSS), as well as clinical outcomes of ovarian stimulation. MAIN RESULTS AND THE ROLE OF CHANCE: Baseline demographic features were not significantly different between the two ovarian stimulation groups. However, in the intention-to-treat (ITT) population, the LBRs in the modified antagonist group were significantly higher than in the conventional group (38.1% [104/273] vs. 27.5% [75/273], relative risk 1.39 [95% CI, 1.09-1.77], P = 0.008). Using a per-protocol (PP) analysis which included all the patients who received an embryo transfer, the LBRs in the modified antagonist group were also significantly higher than in the conventional group (48.6% [103/212] vs. 36.8% [74/201], relative risk 1.32 [95% CI, 1.05-1.66], P = 0.016). The modified antagonist group achieved significantly higher implantation rates, and clinical and ongoing pregnancy rates than the conventional group in both the ITT and PP analyses (P < 0.05). The two groups did not show significant differences between the number of oocytes retrieved or mature oocytes, two-pronuclear zygote (2PN) rates, the number of embryos obtained, blastocyst progression and good-quality embryo rates, early miscarriage rates, or OHSS incidence rates (P > 0.05). LIMITATIONS, REASONS FOR CAUTION: A limitation of our study was that the subjects were not blinded to the treatment allocation in the RCT trial. Only women under 40 years of age who had a good prognosis were included in the analysis. Therefore, use of the modified antagonist protocol in older patients with a low ovarian reserve remains to be investigated. In addition, the sample size for Day 5 elective SET was small, so larger trials will be required to strengthen these findings. WIDER IMPLICATIONS OF THE FINDINGS: The modified GnRH antagonist protocol using the Gn step-down approach and cessation of GnRH antagonist on hCG day improved the LBRs per fresh eSET cycle in normal responders. STUDY FUNDING/COMPETING INTEREST(S): This project was funded by grant 2022YFC2702503 from the National Key Research & Development Program of China and grant 2021140 from the Beijing Health Promotion Association. The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: The RCT was registered in the Chinese Clinical Trial Registry; Study Number: ChiCTR2100053453. TRIAL REGISTRATION DATE: 21 November 2021. DATE OF FIRST PATIENT’S ENROLLMENT: 23 November 2021.
引用
- Xu B, Geerts D, Yuan J, et al. A modified flexible GnRH antagonist protocol using antagonist early cessation and a gonadotropin step-down approach improves live birth rates in fresh cycles: a randomized controlled trial. Hum Reprod. 2024. PMID: 38942602. doi:10.1093/humrep/deae145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。